Evidence map›Paper›PMID 39194209›Full record

ArticleAntimicrobial agents and chemotherapy2024

Dose-fractionation studies of a

Liezl Gibhard, Mathew Njoroge, Mwila Mulubwa, Nina Lawrence, Dennis Smith, James Duffy, Claire Le Manach, Christel Brunschwig, Dale Taylor, Renier van der Westhuyzen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Liezl GibhardHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, South Africa.ORCID 0000-0003-0089-2136
Mathew NjorogeHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, South Africa.
Mwila MulubwaHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, South Africa.
Nina LawrenceHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, South Africa.
Dennis SmithIndependent Researcher, Kent, United Kingdom.
James DuffyMedicines for Malaria Venture, ICC, Geneva, Switzerland.
Claire Le ManachHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, South Africa.
Christel BrunschwigHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, South Africa.
Dale TaylorHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, South Africa.
Renier van der WesthuyzenHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, South Africa.
Leslie J StreetHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, South Africa.
Gregory S BasarabHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, South Africa.ORCID 0000-0001-5684-6046
Kelly ChibaleHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, South Africa.

Funding

Medicines for Malaria Venture (MMV)Neville IsdellSouth African National Research FoundationStrategic Health Innovation Partnerships (SHIP) unit of the South African Medical Research Council (SAMRC)Technology Innovation Agency (TIA)
6 · The paper itself

Abstract

UCT594 is a 2-aminopyrazine carboxylic acid

Indexed as

1-Phosphatidylinositol 4-KinaseAntimalarialsDisease Models, AnimalMalaria, FalciparumPlasmodium falciparumAnimalsDose-Response Relationship, DrugFemaleHumansMiceParasitic Sensitivity Tests1-Phosphatidylinositol 4-KinaseAntimalarials1-phosphatidylinositol 4-kinase inhibitordose-fractionation studiesdrug discoverydrug metabolism and pharmacokineticshuman dose predictionin vivo efficacymalariapharmacokinetic/pharmacodynamic modelling

Identifiers

PMID39194209
PMCPMC11459969

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.